key: cord-0282359-4p1iliaz
authors: Le Rutte, E. A.; Shattock, A. J.; Chitnis, N.; Kelly, S. L.; Penny, M. A.
title: Assessing impact of Omicron on SARS-CoV-2 dynamics and public health burden
date: 2021-12-14
journal: nan
DOI: 10.1101/2021.12.12.21267673
sha: 965875587fb4ecba46171755f0fb5ec6fe16fa5d
doc_id: 282359
cord_uid: 4p1iliaz

SARS-CoV-2 variant Omicron (B.1.1.529) was classified as a variant of concern (VOC) on November 26, 2021. The infectivity, severity, and immune evasion properties of Omicron relative to the Delta variant will determine 1) the probability of dominant future transmission, and 2) the impact on disease burden. Here we apply an individual-based transmission model to identify thresholds for Omicrons potential dominance, impact on health, and risk to health systems; and identify for which combinations of viral properties, current interventions would be sufficient to control transmission. We show that, with first-generation SARS-CoV-2 vaccines and limited physical distancing in place, the threshold for Omicrons future dominance will primarily be driven by its degree of infectivity. However, Omicrons potential dominance may not necessarily lead to increased public health burden. Expanded vaccination that includes a third-dose for adults and child vaccination strategies is projected to have the biggest public health benefit for a highly infective, highly severe variant with low immune evasion capacity. However, a highly immune evading variant that becomes dominant will likely require alternative measures for control, such as strengthened physical distancing measures, novel treatments, and second-generation vaccines. These findings provide quantitative guidance to decision-makers at a critical time while Omicron properties are being assessed. We emphasize the importance of both genomic and population epidemiological surveillance.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint variants. (12) We applied the OpenCOVID model to represent a general European setting and 60 simulated the emergence of a novel variant. We analysed disease dynamics for a wide range of 61 infectivity, severity, and immune evasion properties -relative to the Delta VOC -representing 62 a large range of potential Omicron properties. This allowed us to determine the potential for 63 Omicron to become the new dominant variant, and to estimate its potential future public health 64 burden. We further identified combinations of Omicron's properties for which first-generation 65 vaccines, in the absence of strong NPIs, may be sufficient to contain transmission and public 66 health burden (i.e., new SARS-CoV-2 infections, ICU occupancy, and COVID-19 related 67 deaths) and identified those combinations for which additional measures may be required.

Disease dynamics projections 70 We explored a wide range of potential Omicron infectivity and severity levels (between zero 71 and two) relative to Delta, and the full range of immune evading capacity from 0% (similar to 72 Delta) to 100% (no protection from current vaccines and previously acquired natural immunity 73 after infection). Disease dynamics were simulated over a six-month period beginning 1 74 December 2021 when Omicron emerged, and the cooler weather arrived. We assume an initial 75 effective reproduction number of 1.2, the absence of strict NPIs (e.g., lockdowns), and 76 vaccination coverage by risk group as described in Supplementary Table 1 . 77 We compared two future vaccination scenarios. Firstly, expanded vaccination, with the 78 administration of a third-dose six months after the second dose for individuals older than 12 79 years of age, and administration of vaccines for children aged 5-11 years. Secondly, we 80 simulated a scenario with no future vaccine rollout (no third-dose vaccination in over 12-year 81 olds and no vaccination of 5-11 year-olds). The latter leading to decay of population-level 82 vaccine-induced immunity over time. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint Drivers of Omicron's potential dominance 84 Infectivity and immune evasion were identified as the main drivers behind Omicron's potential 85 dominance, with negligible effect from increasing severity. For an infectivity factor of 1, a 25% 86 immune evasion property is predicted sufficient for dominance, while for a 100% immune 87 evading property an infectivity factor of 0.5 (half the infectivity of Delta) is predicted sufficient. If Omicron is less infective than Delta (below 1), with no immune evading capacity, it would 95 not become dominant and the public health impact due to its emergence will be negligible 96 (Supplementary Figures 2 -3 and Supplementary Table 2 ). Assuming Omicron has partial 97 immune evading capacity (20%) and higher infectivity (1.2) and severity (1.5) than Delta, we 98 predict it would take approximately five months for Omicron to become dominant. We predict 99 these properties to lead to a relatively low public health burden, particularly with expanded 100 vaccination. However, in scenarios where Omicron has higher levels of immune evasion 101 capacity (50%), infectivity (1.5), and severity (2) relative to Delta, dominance can occur within 102 two months, resulting in a high projected public health burden. For most combinations of 103 properties Omicron becomes dominant within two to three months, we predict a high to very 104 high impact on disease burden.

Projected impact on peak ICU occupancy 106 Expanded vaccination is predicted to be sufficient to prevent high ICU occupancy (dark 107 grey/black area of Fig. 1 , capped at 25 ICU beds per 100,000 people) for settings in which Delta 108 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint remains dominant. For a highly infectious (infectivity factor >1.5) but non-immune-evading 109 variant, we predict expanded vaccination may be sufficient to prevent high ICU occupancy, 110 however this probability diminishes with increasing severity. Moreover, there exists a range of 111 infectivity and immune evading properties for which Omicron becomes dominant, but is not 112 expected to lead to high peak ICU occupancy under the assumption of expanded vaccination 113 ( Fig. 1 and dotted area in Fig. 3) . Similarly, this range diminishes with increasing severity. For 114 a variant with infectivity and severity similar to Delta, we predict expanded vaccination will be 115 insufficient to prevent high peak ICU occupancy for an immune evading property above 75%.

For properties that are predicted to lead to high ICU occupancy, settings would benefit from 117 additional measures such as physical distancing, or new treatments and next generation 118 vaccines as they become available. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint vaccination, dashed for no future vaccination). Expanded vaccination includes third-doses for adults 124 (six-months after second-dose) and vaccinating 5-11-year-olds. Rows represent Omicron's potential 125 severity (0 to 2) relative to Delta (1). Horizontal axes represent the range of Omicron's potential 126 infectivity (0 to 2) relative to Delta (1), left vertical axes Omicron's potential immune evading capacity 127 (0 to 100%). The peak ICU occupancy per 100,000 people has been capped at 25 per 100,000, a much 128 higher ICU capacity than most countries. 129 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint Omicron's potential severity (0 to 2) relative to Delta (1), horizontal axes Omicron's potential infectivity 148 (0 to 2) relative to Delta (1) and left vertical axes Omicron's potential immune evading capacity (0 to 149 100%). Maximum percentage of burden averted is capped at 50%, with blue area extending to values 150 >50%. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint on reducing disease burden and health system risk. In case of low severity in area B, expanded Besides additional preventive measures such as strengthened NPIs and second-generation 183 vaccines, new treatments currently under development to reduce ICU occupancy and mortality 184 may need to be implemented. Maximum ICU capacity will have to be considered as it differs 185 between countries, ranging from five to 35 beds per 100,000-population capita in Europe. (15).

In a worst-case scenario of highly immune evading and increased severity of Omicron, for many 187 countries, our predictions reach or surpass maximum ICU capacity. However, very high 188 occupancy rates are unlikely to be reached as countries would implement additional measures 189 sooner.

Although our analysis focuses on ICU occupancy and mortality as a higher priority public is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint planning. Furthermore, as we considered expanding vaccination with third-doses, the global 194 inequity of vaccine access, and the selective pressure and emergence of new variants in settings 195 with low vaccination rates is a global health emergency that needs to be addressed (17).

Our transmission model is based on assumptions that influence its outcomes. In our model pessimistic. Our outcomes would be too optimistic should immunity wane faster than assumed.

A higher or lower value of 1.2 for the effective reproduction number at the start of the winter 208 period, prior to introduction of Omicron, may influence peak ICU occupancy estimates, 209 however the relative impact of vaccination is not sensitive to this parameter. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint immunity. This immunity is assumed to wane over time and can be further reduced if exposed 295 to a novel variant with immune evading properties (Supplementary Table 2 for further details). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint One hundred percent immune evasion means fully evading any previously naturally or is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint Each simulation provided the relative prevalence of Omicron over the next 6 months compared 347 with Delta, as well as daily and cumulative numbers of new SARS-CoV-2 infections, maximum 348 ICU occupancy, and COVID-19-related deaths. To reflect the element of chance that naturally 349 occurs in transmission dynamics, 10 random stochastic simulations were performed per 350 scenario for which we present the mean. In this analysis we do not explore the effect of varying 351 NPI intensity over time. As such, our analysis reflects predicted disease dynamics and public 352 health burden in the absence of strong NPIs, such as lockdowns. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint Competing interests 370 The authors declare no competing interests. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.12.21267673 doi: medRxiv preprint 1. Supplementary Figures 1-6 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 491 We model an interval of 28 days between the first and second dose, and a maximum of 95% 492 vaccine efficacy to be reached 14 days after the second dose (increasing with a sigmoidal 493 curve). We assume that 90% of vaccination effect is transmission blocking. We assume 494 vaccinated individuals will always be administered two doses and assume that 95% of those 495 vaccinated with doses one and two will accept a third-dose. Third-doses are administered 6 496 months after the second dose, after which the maximum vaccine efficacy of 95% is again 497 reached.

After recovering from infection with SARS-CoV-2, individuals develop naturally acquired 500 immunity with a maximum level of 90% transmission blocking effect which they maintain for 501 a month, after which their immunity wanes linearly to zero over a period of 335 days 1,2 . The 502 level of immunity is the reverse of the susceptibility of the individual, which thus increases over 503 time. Immunity immediately after vaccination is also considered 90% in the model, protection 504 against infection, starting two weeks after the second dose has been administered. One month 505 after the second dose, immunity wanes linearly to zero in 335 days.

The probabilities of 1) a symptomatic case developing severe disease, 2) a severe case 508 becoming critical, and 3) a critical case ultimately leading to death, are all defined as functions 509 of age. For this study, we use functions fitted to the probabilities reported in 3 , updated to 510 represent the additional risk of hospitalisation from infection with VOC Delta (B.1.617.2) 4-6 .

In additional to age-related risk, the probability that an infected individual will develop severe 512 symptoms is also scaled by the severity factor of the viral variant exposed to.

In this study we use a severity factor of 1 for VOC Delta (B.1.617.2), and consider a range of Vaccine-induced immunity is assumed to wane over time and can be further decreased if 521 exposed to a variant with immune evading capacity. In this study, we consider the full range of 522 potential immune evading properties of Omicron, from 0% to 100%. For this study, the 523 probabilities that immunologically naïve (i.e., unvaccinated, and previously uninfected) 524 individuals with no comorbidities infected with Delta (severity factor 1, 0% immune evading) 525 develop severe disease are given in Supplementary Table 3 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 537 infection with persisting antibody responses and memory B and T cells

Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 540 dynamics in Switzerland. medRxiv

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta 543 (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

SARS-CoV-2 Delta VOC in Scotland: 546 demographics, risk of hospital admission, and vaccine effectiveness

Risk for COVID-19 Infection, Hospitalization, and Death By Age Group

The authors want to acknowledge and thank the members of the Disease Modelling Unit, Swiss 362 Tropical and Public Health Institute. Calculations were performed at sciCORE